Primary and secondary coenzyme Q10 deficiency: the role of therapeutic supplementation
- PMID: 23452285
- DOI: 10.1111/nure.12011
Primary and secondary coenzyme Q10 deficiency: the role of therapeutic supplementation
Abstract
Coenzyme Q10 (CoQ10) is the only lipid-soluble antioxidant that animal cells synthesize de novo. It is found in cell membranes and is particularly well known for its role in the electron transport chain in mitochondrial membranes during aerobic cellular respiration. A deficiency in either its bioavailability or its biosynthesis can lead to one of several disease states. Primary deficiency has been well described and results from mutations in genes involved in CoQ10 biosynthesis. Secondary deficiency may be linked to hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins), which are used for the treatment of hypercholesterolemia. Dietary contributions of CoQ10 are very small, but supplementation is effective in increasing plasma CoQ10 levels. It has been clearly demonstrated that treatment with CoQ10 is effective in numerous disorders and deficiency states and that supplementation has a favorable outcome. However, CoQ10 is not routinely prescribed in clinical practice. This review explores primary as well as statin-induced secondary deficiency and provides an overview of the benefits of CoQ10 supplementation.
© 2013 International Life Sciences Institute.
Similar articles
-
Statins' effect on plasma levels of Coenzyme Q10 and improvement in myopathy with supplementation.J Am Assoc Nurse Pract. 2014 Feb;26(2):85-90. doi: 10.1002/2327-6924.12046. Epub 2013 Jul 12. J Am Assoc Nurse Pract. 2014. PMID: 24170646 Review.
-
Coenzyme Q10 and statins: biochemical and clinical implications.Mitochondrion. 2007 Jun;7 Suppl:S168-74. doi: 10.1016/j.mito.2007.03.002. Epub 2007 Mar 27. Mitochondrion. 2007. PMID: 17482884 Review.
-
Considerations for supplementing with coenzyme Q10 during statin therapy.Ann Pharmacother. 2006 Feb;40(2):290-4. doi: 10.1345/aph.1G409. Epub 2006 Jan 31. Ann Pharmacother. 2006. PMID: 16449543 Review.
-
HMG-CoA reductase inhibitors and coenzyme Q10.Cardiol Rev. 2005 Mar-Apr;13(2):76-9. doi: 10.1097/01.crd.0000154790.42283.a1. Cardiol Rev. 2005. PMID: 15705257 Review.
-
Effect of treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on serum coenzyme Q10 in diabetic patients.Arzneimittelforschung. 1999 Apr;49(4):324-9. doi: 10.1055/s-0031-1300422. Arzneimittelforschung. 1999. PMID: 10337451 Clinical Trial.
Cited by
-
Association between coenzyme Q 10-related genetic polymorphisms and statin-associated myotoxicity in Korean stroke patients.Front Pharmacol. 2024 May 7;15:1358567. doi: 10.3389/fphar.2024.1358567. eCollection 2024. Front Pharmacol. 2024. PMID: 38774208 Free PMC article.
-
Mutations of GEMIN5 are associated with coenzyme Q10 deficiency: long-term follow-up after treatment.Eur J Hum Genet. 2024 Apr;32(4):426-434. doi: 10.1038/s41431-023-01526-2. Epub 2024 Feb 5. Eur J Hum Genet. 2024. PMID: 38316953
-
Evaluation of the Coenzyme Q10 and Some Biochemical Parameters in Patients with Ischemic Heart Disease.Arch Razi Inst. 2023 Jun 30;78(3):853-861. doi: 10.22092/ARI.2022.359889.2500. eCollection 2023 Jun. Arch Razi Inst. 2023. PMID: 38028821 Free PMC article.
-
Mitochondrial quality control in health and cardiovascular diseases.Front Cell Dev Biol. 2023 Nov 6;11:1290046. doi: 10.3389/fcell.2023.1290046. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 38020895 Free PMC article. Review.
-
The effect of coenzyme Q10 supplementation on liver enzymes: A systematic review and meta-analysis of randomized clinical trials.Food Sci Nutr. 2023 Jun 7;11(9):4912-4925. doi: 10.1002/fsn3.3478. eCollection 2023 Sep. Food Sci Nutr. 2023. PMID: 37701221 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical